This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Edwards Lifesciences Corporation offers products and technologies designed to treat advanced cardiovascular disease worldwide. It provides products for heart valve therapy; critical care; cardiac surgery systems; and vascular diseases. Edwards Life has a market cap of $8.7 billion and is part of the
health care sector. The company has a P/E ratio of 38.7, below the average health services industry P/E ratio of 38.9 and above the S&P 500 P/E ratio of 17.7. Shares are down 6.1% year to date as of the close of trading on Thursday.

TheStreet Ratings rates Edwards Life Sciences as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.